From: Becker's Health IT & CIO Report <>
Subject: [Data analytics/AI] 23andMe, may be under FTC investigation | Why MIT created the 'world's 1st psychopath AI' | Mayo tries to block IRS from questioning CEO | CRISPR may increase cancer risk in humans | 16 hospitals seeking EHR, HIT talent
View our profile on LinkedIn Follow us on Twitter Like us on Facebook Find us on Google+ View our videos on YouTube
June 14, 2018
1. Geisinger researchers are developing a way to predict readmission risk - here's how 

2. CRISPR gene editing may increase cancer risk in humans, two studies suggest 

3. 81% of healthcare execs say they're not prepared for potential social, liability issues of AI 

Learn how to disrupt your health system before Amazon does


5. Hear 210+ speakers from hospitals and health systems focusing on cybersecurity, telehealth, predictive analytics, EMR issues, denials and more at Becker's 4th Annual Health IT + Revenue Cycle Conference in September. Register here. For exhibiting and sponsor opportunities, e-mail

6. Mayo Clinic attempts to block IRS from questioning CEO 

Learn how one CTO leverages single sign-on solutions to make new IT clinician-friendly

FTC may be investigating 23andMe, other DTC genetic testing firms over data privacy 

9. Intermountain soliciting genomics research proposals: 4 things to know 

10. The simple reason MIT researchers created Norman, the 'world's 1st psychopath AI' 

11. Children's healthcare is changing. What do executives need to know? Register for this upcoming webinar to learn more

12. CMS calls on state Medicaid to integrate EHR, PDMP data to fight opioid epidemic 

13. 16 hospitals, health systems seeking Allscripts, Cerner, Epic, Meditech talent 




Contact Us

Editorial Contact: 
Emily Rappleye  
Managing Editor
(312) 948-8556
email editorial

Sales, Marketing & Events:
Jessica Cole
President and CEO
Becker's Hospital Review
A Becker's Healthcare Publication
17 N. State, Suite 1800 | Chicago, IL 60602
ASC Communications, 17 N. State St., Suite 1800, Chicago, IL 60602
Sent by in collaboration with
Constant Contact